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N-acetylcysteine exposure is associated
with improved survival in anti-nuclear
antibody seropositive patients with usual
interstitial pneumonia
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Abstract
Background: Mortality is similarly high among individuals with usual interstitial pneumonia (UIP) due to idiopathic
pulmonary fibrosis (IPF) and interstitial pneumonia with autoimmune features (IPAF). Circulating anti-nuclear
antibodies (ANA) are commonly found in this patient population, suggesting possible aberrant immune activation.
Because an environment of oxidative stress can result from immunologic activation, we hypothesized that ANA
positive patients with UIP would have improved outcome when exposed to the antioxidant N-acetylcysteine (NAC)
compared to ANA negative patients.
Methods: A single center, retrospective cohort analysis was performed. Patients with UIP due to IPF and IPAF were
stratified according to ANA status to and NAC exposure. Transplant-free survival (TFS) was assessed using the Kaplan-
Meier estimator and multivariable Cox regression adjusted for diagnosis, gender/age/physiology score,
immunosuppressant exposure and anti-fibrotic exposure.
Results: Of 293 individuals with UIP due to IPF (74%) or IPAF (26%), NAC exposure was documented in 58 (19.8%).
Among NAC exposed individuals, 33 (56.9%) were ANA seropositive and 25 (43.1%) were seronegative. NAC exposure
was associated with improved TFS survival among ANA seropositive individuals in unadjusted analysis (plogrank = 0.02)
and after multi-variable adjustment (HR 0.51, 95% CI 0.30–0.87; p = 0.01). There was no association between NAC
exposure and TFS in ANA seronegative individuals (HR 1.26, 95% CI 0.69–2.32; p = 0.45). Formal interaction testing
confirmed NAC*ANA interaction (p = 0.04) and sensitivity analysis demonstrated an increasing effect size associated
with NAC therapy as ANA titer increased. Among patients with available genetic data, a marginally higher proportion
of ANA positive patients (p = 0.08) carried the rs3750920 (TOLLIP) genotype previously shown to predict favorable
outcome in NAC exposed patients.
Conclusion: NAC exposure is associated with improved transplant-free survival ANA positive patients with UIP. These
findings support the prospective collection of ANA data in in future NAC clinical trials performed in patients with UIP.
Keywords: Idiopathic pulmonary fibrosis, Interstitial lung disease, Interstitial pneumonia with autoimmune features,
Anti-nuclear autoantibody
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Background
Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative
interstitial lung disease (ILD) of unknown etiology that
results in a progressive loss of lung function and median
survival of 3–5 years [1–3]. Some individuals with IPF
and other forms of idiopathic interstitial pneumonia
(IIP) display features of connective tissue disease (CTD),
but fail to meet established criteria for a specific CTD.
Recognition that such individuals may represent a
unique phenotype led to a recent American Thoracic
Society (ATS)/European Respiratory Society (ERS) joint
research statement that proposed criteria for interstitial
pneumonia with autoimmune features (IPAF) [4]. After
applying IPAF criteria to patients with IPF and other
ILDs, we and other investigators have shown that IPAF
survival was similar to that of IPF, [5, 6] especially
among those with usual interstitial pneumonia (UIP) [6].
While the optimal therapy for patients with IPAF has
yet to be established, a host of randomized clinical trials
have been performed in patients with IPF, including sev-
eral that demonstrated the efficacy of the anti-fibrotic
compounds pirfenidone and nintedanib in slowing pul-
monary function decline [7–9]. Prior to the approval of
anti-fibrotic therapy for IPF, immunosuppressant and
anti-oxidant therapies were routinely used. This practice
effectively ended following the PANTHER trial, due to
increased mortality in those treated with a combination
of prednisone, azathioprine and N-acetylcysteine (NAC)
and lack of efficacy in those treated with NAC mono-
therapy [10, 11].
Our group recently showed that treatment with NAC
therapy may improve outcomes among individuals with
IPF who carry an rs3750920 TT genotype in TOLLIP
[12]. TOLLIP encodes toll-interacting protein, which
regulates downstream inflammatory signaling by inter-
action with toll-like receptors (TLRs) [13, 14]. The TLRs
are critical mediators of airway and alveolar host defense
through recognition of microbial antigens [15]. TLR
activation can also occur upon recognition of self-
antigens bound to autoantibodies, leading to systemic
inflammation characteristic of systemic autoimmune dis-
ease [16–19]. A commonly encountered circulating
autoantibody is the anti-nuclear antibody (ANA), which
is checked in all patients undergoing ILD evaluation at
our institution, and has been described in up to 35% of
patients with IPF [20] and 82% of patients with IPAF [5].
Because antioxidants have been shown to mitigate ex-
perimental models of ANA production [21] and modu-
late oxidative stress caused by TLR activation, [22–24]
we hypothesized that NAC responsiveness would vary
based on ANA status. To test this hypothesis we con-
ducted a retrospective, ANA-stratified cohort analysis of
survival in NAC exposed vs. non-exposed individuals
with UIP due to IPF and IPAF.
Methods
Study design
This investigation was conducted at the University of
Chicago and was approved by the University of Chicago
Institutional Review Board (protocol #14163-A). All pa-
tients included in this study provided written informed
consent. The University of Chicago ILD registry was used
to identify consecutive patients followed from October
2006 to January 2016 with a multi-disciplinary diagnosis
of IPF or IPAF according to ATS/ERS consensus guide-
lines [4, 25]. The electronic medical record was retro-
spectively reviewed to extract pertinent data. A patient
was considered to have therapy exposure when he or she
1) endorsed ongoing use of a medication at the time of
first ILD evaluation or 2) was prescribed at least 3 months
of a medication after establishing care at our institution.
ANA seropositivity was defined as an ANA titer ≥1:320 or
nucleolar or centromere staining pattern at any titer, in ac-
cordance with proposed IPAF criteria [4].
Other information gathered included demographic in-
formation (age, gender, race/ethnicity), patient-reported
medication use including NAC, azathioprine, mycophe-
nolate mofetil, prednisone, pirfenidone and nintedanib,
laboratory studies including antinuclear antibody (ANA)
with immunofluorescence pattern and other autoanti-
bodies (rheumatoid factor, anti-cyclic citrullinated pro-
tein and anti-SSA, anti-SSB, anti-RNP, anti-Smith and
anti-Scl-70 antibodies) and pulmonary function tests, in-
cluding percent predicted forced vital capacity (FVC),
and percent predicted diffusion capacity of the lung for
carbon monoxide (DLCO).
High-resolution computed tomography (HRCT) scans
were reviewed by two chest radiologists with ILD expert-
ise (JC and SM) to determine a consensus radiographic
pattern. IPAF criteria were applied to HRCTs and surgi-
cal lung biopsies (SLB) as previously described [6]. A
possible UIP pattern on HRCT was recorded as UIP, as
possible UIP on HRCT has been shown to strongly cor-
relate with histopathologic UIP [26, 27]. SLB pattern was
considered the final radiographic/histopathologic pattern
when there was discordance between the two diagnostic
modalities. All but two patients with an HRCT pattern
inconsistent with UIP had UIP on SLB. The two patients
without UIP on SLB were considered to have IPF given a
strong family history of pulmonary fibrosis. Vital status
was determined using review of medical records, tele-
phone communication and the social security death
index. Follow-up time was censored on January 1, 2016.
Patients were excluded if they refused consent, did not
undergo ANA testing, had only one ILD clinic visit or
did not have UIP by HRCT or SLB. Genotype data was
available for a subset of individuals included in this
study, which composed the replication cohort of our re-
cent study demonstrating that NAC response may vary
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by TOLLIP rs3750920 genotype [12]. Methods for geno-
type determination were previously reported [12].
Statistical analysis
Continuous variables were reported as means with
standard deviation (SD) or medians with interquartile
range (IQR), as appropriate. Categorical variables were
reported as counts and percentages. Categorical data
were compared using the Chi-square test or Fisher’s
exact test, as appropriate. Survival was assessed using
unadjusted log rank testing along with univariate and
multivariable Cox proportional hazards regression after
ensuring the proportional hazards assumption was met
for each model. Survival curves are plotted using the
Kaplan-Meier survival estimator. Survival time was de-
fined as time from diagnostic test (SLB or HRCT) to
death, transplant, or censoring date (January 1, 2016).
The gender, age, physiology (GAP) index was used as a
surrogate for disease severity in outcomes modeling, as
this index accounts for individuals unable to perform
the DLCO maneuver and has been shown to be a
reliable predictor of mortality [28]. Given the limited
sample size for each of the immunosuppressant and
anti-fibrotic therapies, therapeutic classes were used for
outcomes modeling. Statistical significance was consid-
ered at p < 0.05. All statistical analyses were performed
using Stata (StataCorp. 2013. Release 13. College
Station, TX).
Results
Of 293 patients meeting inclusion criteria (Table 1), 216
(73.7) had IPF and 77 (26.3%) had IPAF-UIP. Among
those with IPAF-UIP, 31 (40.2%) carried a previous diag-
nosis of IPF before application of IPAF criteria. The
mean age of the entire UIP cohort was 67.7 (±8.8) years
with a male predominance (68.6%). The predominant
race was white (82.3%), followed by African American
(8.2%), Hispanic (6.1%) and Asian (3.4%). A history of
smoking was observed in 68% of the cohort. A positive
autoantibody was observed in 167 (61.6%) individuals,
148 (50.5%) of which had a positive ANA (50.5%). On
HRCT, UIP was the predominant pattern (67.5%)
followed by possible UIP (17.1%) and inconsistent with
UIP (15.4%). All patients with possible UIP on HRCT
Table 1 Baseline Characteristics and Outcomes
Variable IPF Cohort (n = 216) IPAF-UIP Cohort (n = 77) Combined UIP Cohort (n = 293)a
Age, mean (±SD) 69.3 (7.8) 63.3 (9.9) 67.7 (8.8)
Male Gender, n (%) 160 (74.1) 41 (53.3) 201 (68.6)
Race, n (%)
White 182 (84.3) 59 (76.6) 241 (82.3)
African American 15 (6.9) 9 (11.7) 24 (8.2)
Hispanic 10 (4.6) 8 (10.4) 18 (6.1)
Asian 9 (4.2) 1 (1.3) 10 (3.4)
Any auto-antibody (+) 93 (43.1) 74 (96.1) 167 (57.0)
ANA (+) b 84 (38.9) 64 (83.1) 148 (50.5)
HRCT, n (%)
UIP 156 (72.2) 41 (54) 197 (67.5)
Possible UIP 36 (16.7) 14 (18.4) 50 (17.1)
Inconsistent with UIP 24 (11.1) 21 (27.6) 45 (15.4)
UIP by SLB c, n (%) 93 (97.9) 55 (100) 148 (98.7)
FVC (% pred), mean (±SD) 67.5 (17.4) 63.5 (16.9) 66.5 (17.4)
DLCO (% pred), mean (±SD) 51.1 (17.1) 48.1 (16.8) 50.3 (17.1)
GAP Score, mean (±SD) 4.1 (1.6) 3.7 (1.6) 4.0 (1.6)
Outcomes
Death 108 (50) 35 (45.5) 143 (48.8)
Transplant 14 (6.5) 14 (18.2) 28 (9.6)
Abbreviations: IPF idiopathic pulmonary fibrosis, IPAF interstitial pneumonia with autoimmune features, ANA anti-nuclear antibody, HRCT high-resolution computed
tomography, UIP usual interstitial pneumonia, SLB surgical lung biopsy, FVC forced vital capacity, DLCO diffusion capacity of the lung for carbon monoxide, GAP
gender, age, physiology
aException for n: Other auto-antibody (n = 88); HRCT (n = 292); UIP by SLB (n = 150); DLCO (n = 272)
bANA titer ≥1:320 or nucleolar or centromere staining pattern at any titer
cTwo patients without UIP by SLB were deemed to have IPF due to family history of pulmonary fibrosis
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who underwent SLB had histologic UIP (n = 28). The
mean percent predicted FVC and DLCO was 66.5% and
50.3%, respectively. The mean GAP score was 4 (±1.6).
Fifty-eight individuals were exposed to NAC, while 235
were not (Table 2). Of these patients, 29 (50%) received
NAC monotherapy, while the rest received NAC and an
immunosuppressant (n = 15) or anti-fibrotic (n = 11).
Three patients received NAC along with immunosuppres-
sant and anti-fibrotic during the study period. The median
NAC exposure time among individuals treated at our in-
stitution was 9.8 months [IQR 4.1–18.1]. There was no
significant difference in prednisone, mycophenolate mofe-
til, pirfenidone or nintedanib exposure use between NAC
exposed and non-exposed cohorts. There was significantly
more azathioprine exposure in the NAC exposed group
when compared to the NAC non-exposed group (13.8%
vs. 3.8%, respectively; p = 0.004) but a similar overall
exposure to immunosuppression between groups (25.9%
vs 22.8%, p = 0.64). Forty-nine percent of patients died
during the follow-up period and nearly 10% received a
lung transplant.
When assessing relevant variables for association with
transplant-free survival (TFS) (Table 3), anti-fibrotic ex-
posure was associated with improved TFS (HR 0.28; 95%
CI 0.14–0.57; p < 0.001), while ANA seropositivity (HR
1.46, 95% CI 1.07–1.98; p = 0.02) and each increase in
GAP score (HR 1.36, 95% CI 1.23–1.51; p < 0.001) were
associated with worse TFS in unadjusted analysis.
Diagnosis (IPAF vs. IPF), NAC exposure, prednisone ex-
posure and azathioprine exposure were not associated
with differential TFS risk. These survival associations
remained in a multivariable model adjusted for ANA
status, diagnosis, NAC exposure, immunosuppressant
exposure, anti-fibrotic exposure and GAP score.
After stratification of the cohort by ANA seropositivity
(Fig. 1) (Table 4), NAC was associated with significantly
improved TFS among ANA seropositive patients (plo-
grank = 0.02; HR 0.55, 95% CI 0.32–0.92), but not among
ANA seronegative patients (plogrank p = 0.92; HR 1.03,
95% CI 0.56–1.87). After adjustment for diagnosis (IPAF
vs. IPF), immunosuppressant exposure, anti-fibrotic
exposure and GAP score, the association between NAC
exposure and improved TFS among ANA seropositive
patients was maintained (HR 0.51, 95% CI 0.30–0.87;
p = 0.01). Anti-fibrotic exposure was associated with
improved TFS in both groups, but only reached stat-
istical significance in the ANA seronegative group
(HR 0.16, 95% CI 0.05–0.51; p = 0.002). IPAF diagno-
sis was also associated with improved TFS in the
ANA seronegative group after multivariable adjust-
ment (HR 0.37; 95% CI 0.14–0.99; p = 0.05).
Significant interaction between NAC exposure and
ANA seropositivity (pinteraction = 0.04) was observed in a
multivariable model that included NAC*ANA inter-
action term and diagnosis, immunosuppressant expos-
ure, anti-fibrotic exposure and GAP score as covariates.
No significant interaction was observed between NAC
exposure and diagnosis, immunosuppressant exposure
or anti-fibrotic exposure using similar models. Sensitivity
analysis was performed to explore the association be-
tween NAC exposure and TFS at various ANA titers
(Table 5). NAC therapy was associated with improved
TFS at all titers, but reached statistical significance at ti-
ters ≥1:320. The strongest effect size was observed in
those with an ANA titer ≥1:1280, but there were a small
number of individuals (n = 14) in this group.
Subgroup analysis was performed to further explore the
association between NAC and improved TFS among those
with ANA seropositivity. NAC remained associated with
improved TFS in those with ANA seropositivity when ex-
cluding individuals who received immunosuppression
(HR 0.41, 95% CI 0.21–0.81; p = 0.01) (Additional file 1:
Table S1), when excluding individuals who received an
anti-fibrotic (HR 0.57; 95% CI 0.33–0.99; p = 0.05)
(Additional file 2: Table S2) and when excluding indi-
viduals who received either an immunsuppressant or
anti-fibrotic (HR 0.46; 95% CI 0.23–0.93; p = 0.03)
(Additional file 3: Table S3). A similar effect size was
Table 2 UIP Cohort Treatment Exposure During Study Period
Therapy NAC Exposed (n = 58) NAC Unexposed (n = 235) p-value
NAC monotherapy 29 (50) 0 (0) < 0.001
Immunosuppressant exposurea 15 (25.9) 54 (22.8) 0.64
Prednisone 15 (25.9) 53 (22.6) 0.59
Azathioprine 8 (13.8) 9 (3.8) 0.004
Mycophenolate mofetil 3 (6.0) 3 (2.8) 0.38
Anti-fibrotic exposure 11 (18.9) 29 (12.3) 0.19
Pirfenidone 10 (17.2) 24 (10.2) 0.13
Nintedanib 1 (1.8) 6 (2.6) 1
Abbreviations: UIP usual interstitial pneumonia, NAC N-acetylcysteine
aAzathioprine/prednisone or mycophenolate/prednisone
Oldham et al. BMC Pulmonary Medicine  (2018) 18:30 Page 4 of 9
observed when considering only those with a diagno-
sis of IPF (HR 0.43, 95% CI 0.21–0.85; p = 0.02)
(Additional file 4: Table S4) and there were an insuffi-
cient number of observations to conduct this analysis
in an IPAF-only cohort.
We then assessed whether ANA status was associated
with rs3750920 (TOLLIP) genotype (Table 6). Among
those for whom these data were available (n = 116), there
was a significant difference in genotype frequency between
ANA seropositive and seronegative patients (p = 0.03).
This difference was driven primarily by differences in the
CT and TT genotypes between groups. When considering
only those with a TT genotype, a higher percentage of
ANA seropositive compared to seronegative patients car-
ried this genotype (40.4% vs. 25.0%), but this difference
was of marginal statistical significance (p = 0.08) in head-
to-head comparison. These findings persisted after stratifi-
cation of the cohort by NAC exposure (Additional file 5:
Table S5), but the analysis was limited by sample sizes in
the NAC exposed group.
Discussion
In this investigation, we showed that NAC responsive-
ness varies by the presence of circulating ANA. We
found that NAC exposure was associated with improved
TFS among ANA seropositive individuals with UIP, but
not among those who were seronegative. This associ-
ation appeared to strengthen as ANA titer increased.
We also showed that there may be an increased fre-
quency of the rs3750920 (TOLLIP) TT genotype in ANA
seropositive patients, which may reflect why such pa-
tients had improved survival when exposed to NAC
Table 3 Variables Predicting Survival in UIP Cohort
Unadjusted (n = 293) Adjusted (n = 293)
Characteristic HR p-value 95% CI HR p-value 95% CI
ANA (+) a 1.46 0.02 1.07–1.98 1.59 0.007 1.13–2.23
NAC exposure 0.74 0.13 0.50–1.09 0.68 0.05 0.44–1.0
IPAF diagnosis b 1.11 0.52 0.80–1.57 0.99 0.97 0.67–1.48
Immunosuppressant exposure c 1.05 0.77 0.74–1.49 0.94 0.75 0.64–1.38
Anti-fibrotic exposure d 0.28 < 0.001 0.14-0.57 0.35 0.004 0.17–0.72
GAP Score 1.36 < 0.001 1.23–1.51 1.36 < 0.001 1.23–1.51
Abbreviations: IPF idiopathic pulmonary fibrosis, IPAF interstitial pneumonia with autoimmune features, UIP usual interstitial pneumonia, NAC N-acetylcysteine,
ANA antinuclear antibody, GAP gender, age, physiology
aANA titer ≥1:320 or nucleolar or centromere staining pattern at any titer
bCompared to IPF diagnosis
cPrednisone, azathioprine or mycophenolate
dPirfenidone or nintedanib
Fig. 1 Transplant-free survival among NAC exposed and non-exposed individuals with UIP stratified by ANA antibody status. Among ANA
seropositive individuals (a), NAC exposed individuals demonstrated improved survival compared to NAC non-exposed individuals (plogrank = 0.02;
HR 0.55, 95% CI 0.32–0.92). Among ANA seronegative individuals (b), survival did not differ between NAC exposed and non-exposed individuals
(plogrank p = 0.92; HR 1.03, 95% CI 0.56–1.87)
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therapy. This study, to our knowledge, is the first to
demonstrate differential UIP treatment response based
on the presence of circulating autoantibodies. These
findings support our previous work showing that NAC
may benefit a subset of patients with IPF [12].
The mechanism by which NAC responsiveness varies in
the presence of circulating autoantibodies remains un-
clear, but TLR signaling may play a role. The TLRs are
critical mediators of innate immunity and TLR2, 3, 4, and
7 are particularly important in airway host defense
through their recognition of inhaled and circulating mi-
crobial antigens. Activation of TLRs generally occurs
through recognition of exogenous pathogen-associated
molecular patterns, which triggers inflammatory signaling
pathways that facilitate infection eradication and stimulate
wound healing [29]. TOLLIP encodes the toll-interacting
protein, an inhibitory adaptor protein that acts down-
stream from TLRs.
TLR activation can also occur by recognition of en-
dogenous damage-associated molecular patterns (DAMPs),
which arise from molecular fragments released from
damaged host cells [30]. Nucleic acid DAMPs within self-
antigens bound to autoantibodies have been shown to
activate TLR3 and TLR7 in systemic lupus erythematosis
[16–19, 31]. The high mobility group box protein 1 DAMP,
released by damaged synovial cells in patients with
rheumatoid arthritis has been shown to activate TLR4 [32].
Extracellular matrix DAMPs that arise during dermal
wound healing in patients with scleroderma have also been
shown to activate TLR4 and enhance the sensitivity of skin
fibroblasts to the fibrogenic effect of transforming growth
factor-β1F [33].
Activation of TLR2, 3, 4 and 7 initiates oxidative sig-
naling, leading to an environment of increased oxidative
stress [22, 24, 34, 35]. NAC has been shown to blunt this
oxidative stress response and can do so in a dose-
dependent manner [22–24]. These observations suggest
that NAC may be mitigating harmful oxidative stress
caused by TLR activation by self-antigen/autoantibody
complexes in ANA seropositive patients with UIP. Con-
versely, we also observed that anti-fibrotic therapy may
be more efficacious in patients without circulating ANA
(Table 4). The reason for this remains unclear, but may
indicate that the blockade of fibrotic pathways is more
effective in the absence of immune activation.
In addition to our primary findings, we also found that
ANA seropositivity was associated with worse outcomes
in this cohort (Table 3). This runs counter to that ob-
served by others, [20, 36] including an earlier study of
autoimmune-featured ILD by our group, [37] which
found that circulating autoantibodies either predicted
improved outcomes, or had no impact on survival. The
percentage of ANA seropositive patients in our cohort is
higher than that reported in other cohorts around the
world, [20, 36] which may explain the discordant results
with regard to mortality risk, and highlights the high
likelihood of regional variability in autoantibody sero-
positivity. We also found that a subset of patients with
IPAF, namely those in the ANA seronegative group, had
improved TFS compared those with IPF (Table 4). This
Table 4 Multivariable-adjusted NAC-associated mortality risk stratified by ANA seropositivitya
ANA (+) a (n = 148) ANA (−) (n = 145)
Characteristic n HR p-value 95% CI n HR p-value 95% CI
NAC exposure 33 0.51 0.01 0.30–0.87 25 1.26 0.45 0.69–2.32
IPAF diagnosis b 64 1.23 0.37 0.78–1.95 13 0.37 0.05 0.14–0.99
Immunosuppressant exposure c 35 0.85 0.54 0.50–1.43 34 1.32 0.32 0.77–2.28
Anti-fibrotic exposure d 20 0.67 0.4 0.27–1.70 22 0.16 0.002 0.05–0.51
GAP Score 148 1.41 < 0.001 1.23–1.61 144 1.27 0.005 1.08–1.50
Abbreviations: NAC N-acetylcysteine, ANA anti-nuclear antibody, IPAF interstitial pneumonia with autoimmune features, GAP gender, age, physiology
aANA titer ≥1:320 or nucleolar or centromere staining pattern at any titer
bCompared to IPF diagnosis
cPrednisone, azathioprine or mycophenolate
dPirfenidone or nintedanib
Table 5 NAC exposure TFS Riska at increasing ANA titers
ANA Titer n HR p-value 95% CI
≥1:160 42 0.67 0.08 0.42–1.05
≥1:320 33 0.51 0.01 0.30–0.87
≥1:640 23 0.52 0.05 0.28–0.99
≥1:1280 14 0.4 0.04 0.16–0.97
Abbreviations: NAC N-acetylcysteine, TFS transplant-free survival, ANA
anti-nuclear antibody
aAdjusted for diagnosis, immunosuppressant exposure, anti-fibrotic exposure
and GAP score
Table 6 rs3750920 (TOLLIP) genotypes stratified by ANA status
ANA Status CC CT TT p-value
ANA (−) (n = 64) 9 (14.1) 39 (60.9) 16 (25) 0.03
ANA (+) (n = 52) 12 (23.1) 19 (36.5) 21 (40.4)
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finding supports our earlier work that identified individuals
with IPAF with a favorable prognosis compared to IPF des-
pite a similar background of UIP [6]. These individuals
tended to have physical manifestations of CTD (IPAF clin-
ical domain) along with features of CTD on HRCT, includ-
ing non-specific interstitial pneumonia and/or organizing
pneumonia (IPAF morphologic domain). Given the vari-
ability in presentation and outcomes of recently character-
ized IPAF cohorts, [5, 6, 38] more research is needed to
identify the optimal therapy for those meeting IPAF criteria.
Our study has several limitations. First the retrospective
nature of this investigation did not allow for assignment
of causation, only association. It is possible that the pres-
ence of unmeasured systematic differences between NAC
exposed and unexposed individuals influenced our results.
Next, our cohort was derived from a single center, which
limits generalizability, especially since the prevalence of
ANA seropositivity appears to vary substantially by geo-
graphical region, [20, 36, 37] and our center has a higher
autoantibody frequency than most others. Complete sero-
logic data was not available for all patients, as current rec-
ommendations do not advise comprehensive serologic
testing for all patients [25]. Our study was also limited by
its small sample size, especially in the NAC exposed
group, which precluded multi-level modeling of NAC re-
sponsiveness at various ANA titers and within IPF and
IPAF disease states. The imbalance in immunosuppressant
and anti-fibrotic therapies between NAC exposed and
non-exposed cohorts also potentially introduced bias, as
did the variability in exposure time with regard to NAC,
immunosuppressants and anti-fibrotics. We conducted a
sensitivity analysis to explore this limitation and found con-
sistent results after exclusion of patients exposed to an im-
munosuppressant and/or anti-fibrotic therapy. (Additional
file 1: Table S1, Additional file 2: Table S2, Additional file 3:
Table S3). Next, our reliance on patient-reported NAC use
did not allow us to confirm NAC duration or dosage for a
large minority of patients exposed to NAC prior to referral
to our institution. As a result, we relied on categorical NAC
exposure for our modeling. The median duration of NAC
exposure among patients treated at our institution was
9 months, suggesting a prolonged course may be necessary.
Conclusion
From this study we conclude that antioxidant therapy may
be efficacious in a subset of patients with UIP, specifically
those with circulating ANA. These findings should be
viewed as hypothesis generating and support the collec-
tion of ANA data in the design of any future NAC clinical
trials to explore further these findings. Replication of these
findings would advance the era of precision medicine
through identification of an immunologically predisposed
subset of patients with UIP for whom NAC may be an ef-
ficacious adjunct to anti-fibrotic therapy.
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